These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 21425164)

  • 1. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.
    Dickinson PA; Kesisoglou F; Flanagan T; Martinez MN; Mistry HB; Crison JR; Polli JE; Cruañes MT; Serajuddin ATM; Müllertz A; Cook JA; Selen A
    J Pharm Sci; 2016 Nov; 105(11):3243-3255. PubMed ID: 27659159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
    Tsong Y; Yang H
    J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
    [No Abstract]   [Full Text] [Related]  

  • 6. Quality cell therapy manufacturing by design.
    Lipsitz YY; Timmins NE; Zandstra PW
    Nat Biotechnol; 2016 Apr; 34(4):393-400. PubMed ID: 27054995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
    Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
    J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The central role of chemistry in 'quality by design' approaches to drug development.
    Grewal NK; Leadbeater NE
    Future Med Chem; 2012 Sep; 4(14):1799-810. PubMed ID: 23043477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
    Gikanga B; Chen Y; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
    Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
    J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quality by design study applied to an industrial pharmaceutical fluid bed granulation.
    Lourenço V; Lochmann D; Reich G; Menezes JC; Herdling T; Schewitz J
    Eur J Pharm Biopharm; 2012 Jun; 81(2):438-47. PubMed ID: 22446063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDA workshop on "Quality by Design for Biopharmaceuticals: Concepts and Implementation", May 21-22, 2007, Bethesda, Maryland.
    Rathore AS; Devine R
    PDA J Pharm Sci Technol; 2008; 62(5):380-90. PubMed ID: 19055233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development.
    Li M; Sander S; Duan J; Rosencrance S; Miksinski SP; Yu L; Seo P; Rege B
    AAPS J; 2016 Nov; 18(6):1406-1417. PubMed ID: 27650190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality by design approach for formulation development: a case study of dispersible tablets.
    Charoo NA; Shamsher AA; Zidan AS; Rahman Z
    Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products.
    Troiano G; Nolan J; Parsons D; Van Geen Hoven C; Zale S
    AAPS J; 2016 Nov; 18(6):1354-1365. PubMed ID: 27631558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.